{"id":"https://openalex.org/W1985685216","doi":"https://doi.org/10.2147/ott.s53164","title":"Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types","display_name":"Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types","publication_year":2015,"publication_date":"2015-04-01","ids":{"openalex":"https://openalex.org/W1985685216","doi":"https://doi.org/10.2147/ott.s53164","mag":"1985685216","pmid":"https://pubmed.ncbi.nlm.nih.gov/25960664","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4410900"},"language":"en","primary_location":{"id":"doi:10.2147/ott.s53164","doi":"https://doi.org/10.2147/ott.s53164","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s53164","pdf_url":"https://www.dovepress.com/getfile.php?fileID=24757","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=24757","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090769354","display_name":"April K.S. Salama","orcid":"https://orcid.org/0000-0002-8105-5374","observed_orcids":["https://orcid.org/0000-0002-8105-5374"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"April K. Salama","raw_affiliation_strings":["Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109331981","display_name":"Tara C. Gangadhar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tara Gangadhar","raw_affiliation_strings":["Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5090769354"],"corresponding_institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.9385,"has_fulltext":true,"cited_by_count":37,"citation_normalized_percentile":{"value":0.72429245,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"8","issue":null,"first_page":"929","last_page":"929"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8270000219345093},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8029999732971191},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9409999847412109},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7129999995231628},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7749999761581421},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.5540000200271606},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6909999847412109},{"id":"https://openalex.org/keywords/resistance-mechanisms","display_name":"resistance mechanisms","score":0.7860000133514404},{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.8650000095367432}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.9583425521850586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7881217002868652},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.666278600692749},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.6390851736068726},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5588080883026123},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.529888927936554},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5004069805145264},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4356693923473358},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4266997277736664},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4222233295440674},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41843512654304504},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4111917018890381},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3917512893676758},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36111125349998474},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.35834163427352905},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3044206202030182}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/ott.s53164","doi":"https://doi.org/10.2147/ott.s53164","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s53164","pdf_url":"https://www.dovepress.com/getfile.php?fileID=24757","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3387140","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4410900","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4410900","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4410900","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Onco Targets Ther","raw_type":"Text"},{"id":"pmid:25960664","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25960664","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:4b40c2f31da345b489cfc5f343146b3a","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/4b40c2f31da345b489cfc5f343146b3a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"OncoTargets and Therapy, Vol 2015, Iss default, Pp 929-937 (2015)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/21455","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/clinical-applications-of-pd-1-based-therapy-a-focus-on-pembrolizumab-m-peer-reviewed-article-OTT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Review"}],"best_oa_location":{"id":"doi:10.2147/ott.s53164","doi":"https://doi.org/10.2147/ott.s53164","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s53164","pdf_url":"https://www.dovepress.com/getfile.php?fileID=24757","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1985685216.pdf","grobid_xml":"https://content.openalex.org/works/W1985685216.grobid-xml"},"referenced_works_count":76,"referenced_works":["https://openalex.org/W159604392","https://openalex.org/W1222874231","https://openalex.org/W1568494625","https://openalex.org/W1828940258","https://openalex.org/W1967884480","https://openalex.org/W1967979334","https://openalex.org/W1969790056","https://openalex.org/W1974193263","https://openalex.org/W1977381583","https://openalex.org/W1978436252","https://openalex.org/W1978857579","https://openalex.org/W1987446429","https://openalex.org/W1990626198","https://openalex.org/W1990675339","https://openalex.org/W1990779902","https://openalex.org/W1996374378","https://openalex.org/W2010121426","https://openalex.org/W2016983859","https://openalex.org/W2021588881","https://openalex.org/W2028045352","https://openalex.org/W2033672531","https://openalex.org/W2035852466","https://openalex.org/W2039566737","https://openalex.org/W2064692482","https://openalex.org/W2087459740","https://openalex.org/W2097855813","https://openalex.org/W2097995306","https://openalex.org/W2098414192","https://openalex.org/W2099468505","https://openalex.org/W2099751212","https://openalex.org/W2100158834","https://openalex.org/W2101653483","https://openalex.org/W2102575291","https://openalex.org/W2103959341","https://openalex.org/W2104748005","https://openalex.org/W2104830962","https://openalex.org/W2107484016","https://openalex.org/W2108933323","https://openalex.org/W2118982164","https://openalex.org/W2119146367","https://openalex.org/W2119896120","https://openalex.org/W2123914905","https://openalex.org/W2128035403","https://openalex.org/W2130066229","https://openalex.org/W2130846254","https://openalex.org/W2134123784","https://openalex.org/W2140875987","https://openalex.org/W2141444851","https://openalex.org/W2143163879","https://openalex.org/W2145973838","https://openalex.org/W2150492554","https://openalex.org/W2152118650","https://openalex.org/W2156383220","https://openalex.org/W2160834915","https://openalex.org/W2160982674","https://openalex.org/W2166084034","https://openalex.org/W2187118450","https://openalex.org/W2211214375","https://openalex.org/W2267696632","https://openalex.org/W2325481887","https://openalex.org/W2329810662","https://openalex.org/W2334872289","https://openalex.org/W2409346424","https://openalex.org/W2471272049","https://openalex.org/W2558718043","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2600478181","https://openalex.org/W2600708922","https://openalex.org/W2606964316","https://openalex.org/W4230195560","https://openalex.org/W4234976411","https://openalex.org/W4235992666","https://openalex.org/W4253292111","https://openalex.org/W4318262605","https://openalex.org/W4319336412"],"related_works":["https://openalex.org/W1988314473","https://openalex.org/W2147803378","https://openalex.org/W2184893160","https://openalex.org/W1984246609","https://openalex.org/W3130761243","https://openalex.org/W2075027825","https://openalex.org/W1963731933","https://openalex.org/W2148047841","https://openalex.org/W1975992327","https://openalex.org/W2561832594"],"abstract_inverted_index":{"Preclinical":[0],"work":[1,121],"has":[2,65],"led":[3],"to":[4,31,50,53,114,131],"an":[5],"increased":[6],"understanding":[7],"of":[8,16,23,62,74,91,140],"the":[9,14,17,41,58,72,89,117,133],"immunomodulatory":[10],"mechanisms":[11,139],"involved":[12,36],"in":[13,20,37,40,45,67,71,106,129],"regulation":[15],"antitumor":[18,134],"response":[19,136],"a":[21,33,68,77],"variety":[22],"tumor":[24,42],"types.":[25],"PD-1":[26],"(programmed":[27],"death":[28],"1)":[29],"appears":[30],"be":[32,51],"key":[34],"checkpoint":[35],"immune":[38,54,135],"suppression":[39],"microenvironment,":[43],"even":[44],"diseases":[46],"not":[47],"previously":[48],"thought":[49],"sensitive":[52],"manipulation.":[55],"More":[56],"recently,":[57],"subsequent":[59],"clinical":[60,98],"development":[61],"PD-1-based":[63],"therapy":[64],"resulted":[66],"major":[69],"breakthrough":[70],"field":[73],"oncology.":[75],"Pembrolizumab,":[76],"humanized":[78],"highly":[79],"selective":[80],"IgG4":[81],"anti-PD-1":[82],"monoclonal":[83],"antibody,":[84],"was":[85],"recently":[86],"approved":[87],"for":[88],"treatment":[90,118],"advanced":[92],"melanoma":[93],"based":[94],"on":[95,124],"promising":[96],"early-phase":[97],"data.":[99],"Encouraging":[100],"results":[101],"have":[102],"also":[103],"been":[104],"seen":[105],"other":[107],"malignancies,":[108],"and":[109,137],"PD-1-targeted":[110],"therapies":[111],"are":[112],"likely":[113],"markedly":[115],"change":[116],"landscape.":[119],"Future":[120],"will":[122],"center":[123],"rationally":[125],"designed":[126],"combination":[127],"strategies":[128],"order":[130],"potentiate":[132],"overcome":[138],"resistance.":[141]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}